Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6437830

COc1ccccc1CN(CC(=O)O)S(=O)(=O)c1ccc2c(N(Cl)C(=N)N)cncc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 7/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TAS2R14 Q9NYV8 5/20 0.39
PLAU P00749 1/20 0.38
DAGLA Q9Y4D2 1/20 0.37
GAA P10253 1/20 0.37
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
TP53 P04637 1/20 0.35
NFE2L2 Q16236 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7371647 0.92 ALDH1A1 (0.39) KEAP1ALDH1A1LMNASMN1; SMN2TAS2R14
Trifluoroacetic Acid SCHEMBL6432836 0.90 PLAU (0.39) KEAP1ALDH1A1LMNASMN1; SMN2TAS2R14
Trifluoroacetic Acid SCHEMBL6435141 0.88 PLAU (0.49) KEAP1ALDH1A1PLAUDAGLA
Trifluoroacetic Acid SCHEMBL6434437 0.83 PLAU (0.46) ALDH1A1LMNATAS2R14PLAUDAGLA
Trifluoroacetic Acid SCHEMBL6432736 0.82 PLAU (0.46) KEAP1ALDH1A1PLAUGAATP53
SCHEMBL6440602 0.81 KEAP1 (0.45) KEAP1ALDH1A1LMNATAS2R14PLAU
Trifluoroacetic Acid SCHEMBL6433676 0.81 PLAU (0.48) KEAP1PLAUNFE2L2
SCHEMBL6433145 0.81 DAGLA (0.47) KEAP1LMNATAS2R14PLAUDAGLA
Hydrochloric Acid SCHEMBL7366869 0.81 PLAU (0.41) KEAP1ALDH1A1PLAUDAGLAGAA
SCHEMBL7377717 0.80 PLAU (0.45) KEAP1ALDH1A1LMNASMN1; SMN2PLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 KEAP1 2747/4885ALDH1A1 2641/4885LMNA 1451/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 KEAP1 2747/4885ALDH1A1 2641/4885LMNA 1451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.